The risk of recurrence following an initial episode of venous thromboembolism is highest in the first 3 months, but remains high for up to 3 years, according to findings from a population-based study involving 2,989 adults.
The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination.
Adding an extra 18 months of warfarin therapy to the standard 6 months of anticoagulation delays the recurrence of venous thrombosis in patients who have a first episode of unprovoked pulmonary embolism.
The FDA has approved a first-in-class angiotensin receptor-neprilysin inhibitor for the reduction of CV death and HF-related hospitalization among patients with HF and reduced ejection fraction, according to a press release.
Older adults with a history of coronary heart disease have a substantially lower cortical volumetric bone mineral density at the distal radius, putting them at risk for fracture, according to research in Osteoporosis International.
Данный сайт и вся информация на нём предназначена для медицинских работников.
Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.